We intend to cure Alzheimer’s disease.

Telocyte offers a novel approach to curing Alzheimer’s, by resetting cell senescence and reversing the fundamental pathology of the disease at the most basic epigenetic level. We reset the age-related behavioral decline of AD using the gene for telomerase, an enzyme that resets gene expression to that of normal young cells. The intervention is uniformly effective in animal studies and is directly applicable to human trials. Both theoretical considerations and animal data make us reasonably confident that we can both prevent and largely reverse the cognitive decline seen in Alzheimer’s patients.

Our FDA-sanctioned, first-in-human trial is planned for 2018.

Telomerase improves behavior and normalizes brain weight, cell function, and behavior in aging animals. Blasco (our collaborator at CNIO) used telomerase gene therapy to reverse age-related cell changes and behavioral decline in aging mice, without increased cancer risk or other adverse effects.

Our FDA-required animal safety study will be completed in 2017, preparatory to our FDA phase 1 human trial in 2018. Telomerase therapy addresses a large, untapped, and growing global market for an effective disease-modifying therapy.